3-醛基苯乙酸 | 34956-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-醛基苯乙酸
• 英文名称: 2-(3-formylphenyl)acetic acid
• 英文别名: (3-formylphenyl)acetic acid
• CAS: 34956-29-1
• 化学式: C₉H₈O₃
• 分子量: 164.161
• InChiKey: IQAJOXWTCPIEQQ-UHFFFAOYSA-N

物化性质

• 熔点：
  92-94 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3))
• 沸点：
  340.0±25.0 °C(Predicted)
• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  温度：2-8°C，保持惰性气体氛围。

反应信息

• 作为反应物：
  描述：

  3-醛基苯乙酸 在 盐酸 作用下， 以 水 为溶剂， 生成 (RS)-carboxymethylphenylglycine
  参考文献：
  名称：

  Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes

  摘要：

  1 We investigated the agonist and atagonist activities of 22 new phenylglycine and phenylalamine derivatives for metabotropic glutamate receptors (mGluRs) by examining their effects on the signal transduction of mGluR(1), mGluR(2) and mGluR(6) subtypes expressed in Chinese hamster ovary cells. This analysis revealed several structural characteristics that govern receptor subtype specificity of the agonist and antagonist activities of phenylglycine derivatives.2 Hydroxyphenylglycine derivatives possessed either an agonist activity on mGluR(1) mGluR(6) or an antagonist activity on mGluR(1).3 Carboxyphenylglycine derivatives showed an agonist activity on mGluR(2) but an antagonist activity on mGluR(1).4 alpha-Methylation or alpha-ethylation of the carboxyphenylglycine derivatives converts the agonist property For mGluR(2) to an antagonist property, thus producing antagonists at both mGluR(1) and mGluR(2).5 Structurally-corresponding phenylalanine derivatives showed little or no agonist or antagonist activity on any subtypes of the receptors.6 This investigation demonstrates that the nature and positions of side chains and ring substituents incorporated into the phenylglycine structure are critical in determining the agonist and antagonist activities of members of this group of compounds on different subtypes of the mGluR family.7 We also tested two alpha-methyl derivatives of mGluR agonists. (2S, 1'S, 2'S)-2-(2-Carboxycyciopropyl)glycine (L-CCG-I) is a potent agonist for mGluR(2) but alpha-methylation of this compound changes its activity to that of an mGluR(2)-selective antagonist. In contrast, alpha-methylation of L-2-amino-4-phosphonobutyrate (L-AP4) results in retention of an agonist activity on mCluR(6). Thus, alpha-methylation produces different effects, depending on the chemical structures of lead compounds and/or on the subtype of mGluR tested.

  DOI：

  10.1111/j.1476-5381.1996.tb15312.x
• 作为产物：
  描述：

  3-甲酰基苯乙酸甲酯 在 甲醇 、 lithium hydroxide 、 水 、 盐酸 作用下， 生成 3-醛基苯乙酸
  参考文献：
  名称：

  WO2007/51062

  摘要：

  公开号：

文献信息

• [EN] OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY<br/>[FR] OXINDOLES SUBSTITUÉS PAR OLÉFINE AYANT UNE ACTIVITÉ SUR AMPK
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014202528A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有有价值的药理特性的式(I)化合物，特别是AMPK激活剂，因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• Identification of a New Class of Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors Followed by a Structure–Activity Relationship Study
  作者：Stinne W. Hansen、Mette N. Erichsen、Bingru Fu、Walden E. Bjørn-Yoshimoto、Bjarke Abrahamsen、Jacob C. Hansen、Anders A. Jensen、Lennart Bunch

  DOI：10.1021/acs.jmedchem.6b01058

  日期：2016.10.13

  Screening of a small compound library at the three excitatory amino acid transporter subtypes 1–3 (EAAT1–3) resulted in the identification of compound (Z)-4-chloro-3-(5-((3-(2-ethoxy-2-oxoethyl)-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid (1a) that exhibited a distinct preference as an inhibitor at EAAT1 (IC50 20 μM) compared to EAAT2 and EAAT3 (IC50 > 300 μM). This prompted us to

  在三种兴奋性氨基酸转运蛋白亚型1-3（EAAT1-3）上筛选小型化合物文库，从而鉴定出化合物（Z）-4-氯-3-（5-（（3-（2-乙氧基- （2-氧代乙基）-2,4-二氧噻唑烷-5-亚甲基）呋喃-2-基）苯甲酸（1a）与EAAT2和EAAT3（EA 50）相比在EAAT1（IC 50 20μM）上表现出明显的抑制作用（ IC 50 > 300μM）。这促使我们接受主题1a通过购买，合成和随后的总共36种类似物的药理学表征，进行详细的构效关系研究。尽管这种努力并未导致与通过点击显示的类似物在EAAT1上具有显着改善的抑制效能，但它提供了对该支架的EAAT1活性的结构要求的详细见解。这类新的EAAT1选择性抑制剂的发现不仅补充了EAAT领域目前可用的药理学工具，而且证实了非α-氨基酸衍生的EAAT配体在亚型选择性调节方面具有相当大的潜力。运输者。
• N-&lsqb;5-&lsqb;&lsqb;&lsqb;5-alkyl-2-oxazolyl&rsqb;methyl&rsqb;thio&rsqb;-2-thiazolyl&rsqb;-carboxamide inhibitors of cyclin dependent kinases
  申请人：Bristol-Myers Squibb Company

  公开号：US06214852B1

  公开（公告）日：2001-04-10

  The present invention describes compounds of formula I and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.

  本发明描述了式I的化合物及其对映体、二对映体和药学上可接受的盐。式I化合物是蛋白激酶抑制剂，可用于治疗增殖性疾病，例如癌症、炎症和关节炎。它们也可能对治疗阿尔茨海默病、化疗诱导的脱发和心血管疾病有用。